Cargando…

Eteplirsen in the treatment of Duchenne muscular dystrophy

Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500–5,000 male births that is characterized by progressive muscular deterioration. It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Kenji Rowel Q, Maruyama, Rika, Yokota, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338848/ https://www.ncbi.nlm.nih.gov/pubmed/28280301 http://dx.doi.org/10.2147/DDDT.S97635

Ejemplares similares

Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2018)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges
por: Echigoya, Yusuke, et al.
Publicado: (2018)

Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
por: Alfano, Lindsay N., et al.
Publicado: (2019)

Genotype–Phenotype Correlations in Duchenne and Becker Muscular Dystrophy Patients from the Canadian Neuromuscular Disease Registry
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2021)

Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA
por: Iff, Joel, et al.
Publicado: (2023)

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2016)

Eteplirsen Use in a Boy with Duchenne Muscular Dystrophy and Sickle Cell Anemia
por: Aiello, Gregory M., et al.
Publicado: (2022)

DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019)

Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2022)

Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy
por: Nguyen, Quynh, et al.
Publicado: (2019)

CRISPR Therapeutics for Duchenne Muscular Dystrophy
por: Erkut, Esra, et al.
Publicado: (2022)

Cardiac therapies for Duchenne muscular dystrophy
por: Shah, Md Nur Ahad, et al.
Publicado: (2023)

Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History
por: Kinane, T. Bernard, et al.
Publicado: (2018)

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial
por: McDonald, Craig M., et al.
Publicado: (2021)

Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy
por: Wilton-Clark, Harry, et al.
Publicado: (2023)

Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls
por: Mendell, Jerry R., et al.
Publicado: (2021)

Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy
por: Bittel, Adam J., et al.
Publicado: (2020)

Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience
por: Roshmi, Rohini Roy, et al.
Publicado: (2021)

Current Translational Research and Murine Models For Duchenne Muscular Dystrophy
por: Rodrigues, Merryl, et al.
Publicado: (2016)

Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy
por: Nguyen, Quynh, et al.
Publicado: (2017)

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013)

Advances in Genetic Characterization and Genotype–Phenotype Correlation of Duchenne and Becker Muscular Dystrophy in the Personalized Medicine Era
por: Sheikh, Omar, et al.
Publicado: (2020)

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019)

Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot
por: Wilton-Clark, Harry, et al.
Publicado: (2022)

CRISPR technologies for the treatment of Duchenne muscular dystrophy
por: Choi, Eunyoung, et al.
Publicado: (2021)

CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
por: Wilton-Clark, Harry, et al.
Publicado: (2023)

A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the DMD Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis
por: Anwar, Saeed, et al.
Publicado: (2021)

Nutritional Challenges in Duchenne Muscular Dystrophy
por: Salera, Simona, et al.
Publicado: (2017)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

The Duchenne muscular dystrophy gene and cancer
por: Jones, Leanne, et al.
Publicado: (2020)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Gene Therapy for Duchenne Muscular Dystrophy
por: Elangkovan, Nertiyan, et al.
Publicado: (2021)

Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies
por: Nguyen, Quynh, et al.
Publicado: (2020)

Current and emerging treatment strategies for Duchenne muscular dystrophy
por: Mah, Jean K
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vn42lfqdvesj4im5s1eg2qd6vo